Overview

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This Phase 3, multi-center study will evaluate the long-term safety and tolerability of hydrocodone bitartrate controlled release capsule (HC-CR) at daily doses of 40 mg or more in subjects with moderate to severe chronic pain. Long-term maintenance of HC-CR efficacy will be evaluated.
Phase:
Phase 3
Details
Lead Sponsor:
Zogenix, Inc.
Treatments:
Hydrocodone